FEDERALhearing transcript

Senate Hearing on Alzheimer's Diagnosis and Care Barriers

Original title: ALZHEIMER'S AWARENESS: BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE COORDINATION

January 1, 2021

Alzheimer's disease healthcare access medical diagnosis care coordination gerontology

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing serves as a formal record of expert testimony and stakeholder input that informs future federal policy, Medicare coverage, and healthcare funding decisions regarding Alzheimer's disease management.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Alzheimer's patients and families

They are the primary subjects of the care coordination and diagnostic barriers discussed in the hearing.

Healthcare providers

They are responsible for implementing diagnostic protocols and care coordination strategies discussed by the committee.

What changed

Last recorded activity January 1, 2021.

What's next

Next step not available in the current record.

Summary

The Senate Finance Subcommittee on Health Care held a hearing on November 20, 2019, to examine the challenges patients face in receiving timely Alzheimer's diagnoses, effective treatments, and coordinated care. Experts and advocates provided testimony on the current state of Alzheimer's care and potential improvements to the healthcare system.

Key Facts

The hearing was held on November 20, 2019, in the Dirksen Senate Office Building.
The hearing focused on identifying barriers to diagnosis, treatment, and care coordination for Alzheimer's patients.
Four expert witnesses provided testimony: Dr. Jason Karlawish, Janet Tomcavage, Dr. Marc A. Cohen, and Lauren Kovach.
The hearing record includes submitted statements from various organizations, including the Alzheimer's Foundation of America and America's Health Insurance Plans.
Witnesses provided written responses to follow-up questions from subcommittee members, which are included in the official record.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was convened to discuss the difficulties patients face in getting diagnosed with Alzheimer's, accessing treatments, and coordinating long-term care.

Who testified at the hearing?

The witnesses included a medical professor, a chief nursing executive, a professor, and an Alzheimer's advocate.

Why It Matters

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Care Coordination

The hearing highlights a shift in legislative focus from purely drug-based research to the systemic challenges of care coordination for Alzheimer's patients.

Subcommittee on Health Care

Connected Entities

personJanet Tomcavage“Witness, Chief Nursing Executive at Geisinger”Map →

organizationSubcommittee on Health Care“Senate body conducting the hearing”Map →

personLauren Kovach“Witness, Alzheimer's advocate”Map →

personDebbie Stabenow“Ranking member of the Subcommittee on Health Care”Map →

personMarc A. Cohen“Witness, Professor of Gerontology at UMass Boston”Map →

personPatrick J. Toomey“Chairman of the Subcommittee on Health Care”Map →

personJason Karlawish“Witness, Professor of Medicine and Neurology at University of Pennsylvania”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Publisher tools